💰 Financial Performance

Geographic Revenue Split

Not disclosed in available documents, though the company engages in international trade primarily in USD and Euro.

Credit Rating & Borrowing

The company last obtained a credit rating in 2014; no fresh credit rating was obtained for debt instruments or fund mobilization in FY 2023-24.

⚙️ Operational Drivers

Raw Materials

Raw materials (unspecified) are imported for a few products, but specific names and cost percentages are not disclosed.

📈 Strategic Growth

Products & Services

Finished goods (pharmaceutical formulations) and raw materials for specific products.

🌍 External Factors

Industry Trends

The company operates in the pharmaceutical sector (Formulations & Development). The industry is evolving toward stricter compliance with Indian Accounting Standards (Ind-AS), which the company adopted on April 1, 2017.

Geopolitical Risks

Exposure to international trade in USD and Euro makes the company sensitive to global currency stability.

⚖️ Regulatory & Governance

Industry Regulations

The company must comply with SEBI (LODR) Regulations 2015 and Indian Accounting Standards (Ind-AS). It is subject to secretarial audits and reconciliation of share capital audits.

Legal Contingencies

NSE and BSE imposed a fine of INR 5,000 each (INR 10,000 total) for a delay in submitting related party disclosures for the half-year ended March 2022. No other penalties or strictures were imposed by statutory authorities in the last 3 years.

⚠️ Risk Analysis

Key Uncertainties

Foreign exchange risk due to international trade in USD and Euro. Market price volatility is evident as the stock price ranged from a low of INR 7.05 to a high of INR 24.29 during FY 2023-24.